Lubberman F, Gelderblom H, Hamberg P, et al. A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs? ASCO Annual Meeting 2019, abstract 4564.
Betere ziektevrije overleving met adjuvant olaparib bij BRCA1- of BRCA2-gemuteerde borstkanker
sep 2021 | Borstkanker